Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 Dose-finding Study in Type 2 Diabetes
NCT01824264Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Novartis. Primary endpoint: Change from baseline in glycated hemoglobin at 12 weeks. Planned start Nov 2015; status: withdrawn.
02
Drugs
licogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01824264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824264.